SYNOPSYS INC, DEF 14A filed on 2/19/2026
Proxy Statement (definitive)
v3.25.4
Cover
 12 Months Ended
Oct. 31, 2025
Document Information [Line Items]  
Document Type DEF 14A
Amendment Flag false
Entity Information [Line Items]  
Entity Registrant Name Synopsys, Inc.
Entity Central Index Key 0000883241
v3.25.4
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Oct. 31, 2025
Oct. 31, 2024
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
YearSummary
Compensation
Table Total for
Sassine Ghazi¹
($)
Compensation
Actually Paid
to Sassine
Ghazi¹˒²˒³
($)
Summary
Compensation
Table Total
for Dr. Aart J.
de Geus¹
($)
Compensation
Actually Paid
to Dr. Aart J.
de Geus¹˒²˒³
($)
Summary
Compensation
Table Total
for Dr. Chi-Foon Chan¹
($)
Compensation
Actually
Paid to
Dr. Chi-Foon
Chan¹˒²˒³
($)
Average
Summary
Compensation
Table Total
for Non-PEO
NEOs¹
($)
Average
Compensation
Actually Paid
to Non-PEO
NEOs¹˒²˒³
($)
Value of Initial
Fixed $100
Investment
based on:4
Net
Income5
($ Millions)
Revenue5,6
($ Millions)
Total
Stockholder
Return
($)
Peer
Group
Total
Stockholder
Return
($)
(a)(b)(b)(c)(c)(d)(e)(f)(g)(h)(i)
2025
19,605,963
(15,589,671)
—
—
—
—
4,837,777
(6,058,698)
212.2
318.9
1,333
7,054
202427,404,261 30,466,869 8,963,359 15,455,755 — — 6,229,241 9,084,048 240.16 231.83 2,236 6,127 
2023— — 12,681,076 34,149,432 — — 7,755,213 16,756,632 213.69 150.63 1,218 5,318 
2022— — 10,058,495 10,852,624 359,853 (23,874,312)4,531,826 4,697,917 138.33 118.75 978 4,616 
2021— — 9,974,985 34,724,593 9,976,485 34,726,093 5,752,339 17,052,055 155.79 146.93 756 4,204 
        
Company Selected Measure Name Revenue        
Named Executive Officers, Footnote The individuals comprising the PEO NEOs for each year presented are listed below.
2021
2022
2023
2024
2025
Dr. Aart J. de Geus
Dr. Aart J. de Geus
Dr. Aart J. de Geus
Dr. Aart J. de Geus
Sassine Ghazi
Chi-Foon Chan
Chi-Foon Chan

Sassine Ghazi

The individuals comprising the Non-PEO NEOs for each year presented are listed below.
20212022202320242025
Sassine GhaziSassine GhaziSassine GhaziShelagh GlaserDr. Aart J. de Geus
Trac PhamTrac PhamTrac PhamRick MahoneyShelagh Glaser
Joseph W. LoganJoseph W. LoganShelagh GlaserJohn F. Runkel, Jr.Janet Lee
John F. Runkel, Jr.John F. Runkel, Jr.Rick MahoneyRick Mahoney
John F. Runkel, Jr.John F. Runkel, Jr.
        
Peer Group Issuers, Footnote The Peer Group TSR set forth in this table utilizes the S&P 500 Information Technology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our 2025 Annual Report on Form 10-K. The comparison assumes $100 was invested for the period starting October 31, 2020, through the end of the listed year in Synopsys and in the S&P 500 Information Technology Index, respectively. Historical stock performance is not intended to forecast nor be indicative of the future stock performance of our common stock.        
Adjustment To PEO Compensation, Footnote Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEOs and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards columns below are the totals derived from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.
YearSummary
Compensation
Table Total for
Sassine Ghazi
($)
Exclusion of Stock
Awards and Option
Awards for
Sassine Ghazi
($)
Inclusion of Equity
Values for
Sassine Ghazi
($)
Compensation
Actually Paid to
Sassine Ghazi
($)
202519,605,963 (17,519,786)(17,675,848)(15,589,671)
Year
Average Summary
Compensation Table
Total for
Non-PEO NEOs
($)
Average Exclusion
of Stock Awards
and Option Awards
for Non-PEO NEOs
($)
Average Inclusion
of Equity Values
for Non-PEO NEOs
($)
Average
Compensation
Actually Paid to
Non-PEO NEOs
($)
20254,837,777 (4,152,935)(6,743,540)(6,058,698)
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
YearYear-End Fair
Value of Equity
Awards Granted
During Year
That Remained
Unvested as of
Last Day of
Year for
Sassine Ghazi
($)		Change in Fair
Value from Last
Day of Prior
Year to Last
Day of Year of
Unvested Equity
Awards for
Sassine Ghazi
($)		Vesting-Date Fair
Value of Equity
Awards Granted
During Year
that Vested
During Year for
Sassine Ghazi
($)		Change in Fair
Value from Last
Day of Prior
Year to Vesting
Date of Unvested
Equity Awards
that Vested
During Year for
Sassine Ghazi
($)		Fair Value at
Last Day of
Prior Year of
Equity Awards
Forfeited During
Year for
Sassine Ghazi
($)
Total - Inclusion
of Equity
Values for
Sassine Ghazi
($)
20258,810,795 (23,655,246)— (2,831,397)— (17,675,848)

Year
Average
Year-End Fair
Value of Equity
Awards Granted
During Year
That Remained
Unvested as of
Last Day of
Year for
Non-PEO NEOs
($)
Average Change
in Fair Value
from Last Day of
Prior Year to
Last Day of Year of
Unvested Equity
Awards for
Non-PEO NEOs
($)
Average
Vesting-Date
Fair Value of
Equity Awards
Granted During
Year that
Vested During
Year for
Non-PEO NEOs
($)
Average Change
in Fair Value
from Last Day of
Prior Year to
Vesting Date of
Unvested Equity
Awards that
Vested During
Year for
Non-PEO NEOs
($)
Average Fair
Value at Last
Day of Prior
Year of Equity
Awards Forfeited
During Year for
Non-PEO NEOs
($)
Total - Average
Inclusion of
Equity Values for
Non-PEO NEOs
($)
20252,408,279 (7,519,039)— (1,632,780)— (6,743,540)
        
Non-PEO NEO Average Total Compensation Amount $ 4,837,777 $ 6,229,241 $ 7,755,213 $ 4,531,826 $ 5,752,339
Non-PEO NEO Average Compensation Actually Paid Amount $ (6,058,698) 9,084,048 16,756,632 4,697,917 17,052,055
Adjustment to Non-PEO NEO Compensation Footnote Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEOs and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards columns below are the totals derived from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.
YearSummary
Compensation
Table Total for
Sassine Ghazi
($)
Exclusion of Stock
Awards and Option
Awards for
Sassine Ghazi
($)
Inclusion of Equity
Values for
Sassine Ghazi
($)
Compensation
Actually Paid to
Sassine Ghazi
($)
202519,605,963 (17,519,786)(17,675,848)(15,589,671)
Year
Average Summary
Compensation Table
Total for
Non-PEO NEOs
($)
Average Exclusion
of Stock Awards
and Option Awards
for Non-PEO NEOs
($)
Average Inclusion
of Equity Values
for Non-PEO NEOs
($)
Average
Compensation
Actually Paid to
Non-PEO NEOs
($)
20254,837,777 (4,152,935)(6,743,540)(6,058,698)
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
YearYear-End Fair
Value of Equity
Awards Granted
During Year
That Remained
Unvested as of
Last Day of
Year for
Sassine Ghazi
($)		Change in Fair
Value from Last
Day of Prior
Year to Last
Day of Year of
Unvested Equity
Awards for
Sassine Ghazi
($)		Vesting-Date Fair
Value of Equity
Awards Granted
During Year
that Vested
During Year for
Sassine Ghazi
($)		Change in Fair
Value from Last
Day of Prior
Year to Vesting
Date of Unvested
Equity Awards
that Vested
During Year for
Sassine Ghazi
($)		Fair Value at
Last Day of
Prior Year of
Equity Awards
Forfeited During
Year for
Sassine Ghazi
($)
Total - Inclusion
of Equity
Values for
Sassine Ghazi
($)
20258,810,795 (23,655,246)— (2,831,397)— (17,675,848)

Year
Average
Year-End Fair
Value of Equity
Awards Granted
During Year
That Remained
Unvested as of
Last Day of
Year for
Non-PEO NEOs
($)
Average Change
in Fair Value
from Last Day of
Prior Year to
Last Day of Year of
Unvested Equity
Awards for
Non-PEO NEOs
($)
Average
Vesting-Date
Fair Value of
Equity Awards
Granted During
Year that
Vested During
Year for
Non-PEO NEOs
($)
Average Change
in Fair Value
from Last Day of
Prior Year to
Vesting Date of
Unvested Equity
Awards that
Vested During
Year for
Non-PEO NEOs
($)
Average Fair
Value at Last
Day of Prior
Year of Equity
Awards Forfeited
During Year for
Non-PEO NEOs
($)
Total - Average
Inclusion of
Equity Values for
Non-PEO NEOs
($)
20252,408,279 (7,519,039)— (1,632,780)— (6,743,540)
        
Compensation Actually Paid vs. Total Shareholder Return
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, Synopsys' cumulative TSR, and our Peer Group TSR, in each case, over the five most recently completed fiscal years. In June 2022, Dr. Chi-Foon Chan departed from his role as co-Chief Executive Officer, at which point his unvested awards terminated, resulting in negative ‘compensation actually paid’ for those forfeited awards.
PEO AND AVERAGE NON-PEO NEO COMPENSATION ACTUALLY PAID
VERSUS COMPANY TSR AND S&P 500 INFORMATION TECHNOLOGY TSR
03_Synopsis_NET INCOME AND REVENUE.jpg
03_PRO013450_barchart_peo-and-nonpeo compensation-03.jpg 
Sassine Ghazi Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-04.jpg 
Dr. Aart J. de Geus Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-06.jpg 
Dr. Chi-Foon Chan Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-05.jpg 
Average Non-PEO NEO Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-08.jpg 
Synopsys, Inc. TSR
03_PRO013450_barchart_peo-and-nonpeo compensation-07.jpg 
S&P 500 Information Technology Index TSR
        
Compensation Actually Paid vs. Net Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, our Net Income and our Revenue, in each case, during the five most recently completed fiscal years. In June 2022, Dr. Chi-Foon Chan departed from his role as co-Chief Executive Officer, at which point his unvested awards terminated, resulting in negative ‘compensation actually paid’ for those forfeited awards.
PEO AND AVERAGE NON-PEO NEO COMPENSATION ACTUALLY PAID
VERSUS NET INCOME AND REVENUE
03_Synopsis_TSR AND S&P.jpg
03_PRO013450_barchart_peo-and-nonpeo compensation-03.jpg 
Sassine Ghazi Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-04.jpg 
Dr. Aart J. de Geus Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-06.jpg 
Dr. Chi-Foon Chan Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-05.jpg 
Average Non-PEO NEO Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-07.jpg 
Synopsys, Inc. Net Income
03_PRO013450_barchart_peo-and-nonpeo compensation-08.jpg 
Synopsys, Inc. Revenue
        
Compensation Actually Paid vs. Company Selected Measure
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, our Net Income and our Revenue, in each case, during the five most recently completed fiscal years. In June 2022, Dr. Chi-Foon Chan departed from his role as co-Chief Executive Officer, at which point his unvested awards terminated, resulting in negative ‘compensation actually paid’ for those forfeited awards.
PEO AND AVERAGE NON-PEO NEO COMPENSATION ACTUALLY PAID
VERSUS NET INCOME AND REVENUE
03_Synopsis_TSR AND S&P.jpg
03_PRO013450_barchart_peo-and-nonpeo compensation-03.jpg 
Sassine Ghazi Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-04.jpg 
Dr. Aart J. de Geus Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-06.jpg 
Dr. Chi-Foon Chan Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-05.jpg 
Average Non-PEO NEO Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-07.jpg 
Synopsys, Inc. Net Income
03_PRO013450_barchart_peo-and-nonpeo compensation-08.jpg 
Synopsys, Inc. Revenue
        
Total Shareholder Return Vs Peer Group
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, Synopsys' cumulative TSR, and our Peer Group TSR, in each case, over the five most recently completed fiscal years. In June 2022, Dr. Chi-Foon Chan departed from his role as co-Chief Executive Officer, at which point his unvested awards terminated, resulting in negative ‘compensation actually paid’ for those forfeited awards.
PEO AND AVERAGE NON-PEO NEO COMPENSATION ACTUALLY PAID
VERSUS COMPANY TSR AND S&P 500 INFORMATION TECHNOLOGY TSR
03_Synopsis_NET INCOME AND REVENUE.jpg
03_PRO013450_barchart_peo-and-nonpeo compensation-03.jpg 
Sassine Ghazi Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-04.jpg 
Dr. Aart J. de Geus Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-06.jpg 
Dr. Chi-Foon Chan Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-05.jpg 
Average Non-PEO NEO Compensation Actually Paid
03_PRO013450_barchart_peo-and-nonpeo compensation-08.jpg 
Synopsys, Inc. TSR
03_PRO013450_barchart_peo-and-nonpeo compensation-07.jpg 
S&P 500 Information Technology Index TSR
        
Tabular List, Table
Revenue
Compound Annual Growth Rate of Revenue
Non-GAAP Operating Margin
Backlog(1)
rTSR(2)
        
Total Shareholder Return Amount $ 212.2 240.16 213.69 138.33 155.79
Peer Group Total Shareholder Return Amount 318.9 231.83 150.63 118.75 146.93
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ 1,333,000,000 $ 2,236,000,000 $ 1,218,000,000 $ 978,000,000 $ 756,000,000
Company Selected Measure Amount 7,054,000,000 6,127,000,000 5,318,000,000 4,616,000,000 4,204,000,000
Additional 402(v) Disclosure The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by Synopsys' NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.On September 30, 2024, we completed the sale of our Software Integrity Group. Net Income and Revenue are presented on a continuing operations basis for fiscal 2022, 2023 and 2024, which excludes the results of the Software Integrity Group during those fiscal years. Our financial statements for fiscal 2021 were not revised to reflect the sale of the Software Integrity Group and therefore Net Income and Revenue for fiscal 2021 include the results of the Software Integrity Group.We determined Revenue, as calculated in accordance with GAAP, to be our Company-Selected Measure as we deem it to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEOs and Non-PEO NEOs in 2025. “Backlog” means contracted but unsatisfied or partially unsatisfied performance obligations as of October 31, 2025, which includes non-cancellable Flexible Spending Account (FSA) commitments from customers where actual product selection and quantities of specific products or services are to be determined by customers at a later date, and excludes future sales-based royalty payments from the remaining performance obligations. Approximately 45% of the backlog as of October 31, 2025, excluding non-cancellable FSA, is expected to be recognized as revenue over the next 12 months, with the remainder recognized thereafter. The majority of the remaining backlog is expected to be recognized in the following three years. "rTSR" measures Synopsys' stock price ranking as measured against the S&P 500 Information Technology Sector Index.        
Measure:: 1          
Pay vs Performance Disclosure          
Name Revenue        
Measure:: 2          
Pay vs Performance Disclosure          
Name Compound Annual Growth Rate of Revenue        
Measure:: 3          
Pay vs Performance Disclosure          
Name Non-GAAP Operating Margin        
Measure:: 4          
Pay vs Performance Disclosure          
Name Backlog(1)        
Measure:: 5          
Pay vs Performance Disclosure          
Name rTSR(2)        
Sassine Ghazi [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount $ 19,605,963 $ 27,404,261      
PEO Actually Paid Compensation Amount $ (15,589,671) $ 30,466,869      
PEO Name Sassine Ghazi Sassine Ghazi      
Aart J. de Geus [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount   $ 8,963,359 $ 12,681,076 $ 10,058,495 $ 9,974,985
PEO Actually Paid Compensation Amount   $ 15,455,755 $ 34,149,432 $ 10,852,624 $ 34,724,593
PEO Name   Dr. Aart J. de Geus Dr. Aart J. de Geus Dr. Aart J. de Geus Dr. Aart J. de Geus
Chi-Foon Chan [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount       $ 359,853 $ 9,976,485
PEO Actually Paid Compensation Amount       $ (23,874,312) $ 34,726,093
PEO Name       Chi-Foon Chan Chi-Foon Chan
PEO | Sassine Ghazi [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (17,519,786)        
PEO | Sassine Ghazi [Member] | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (17,675,848)        
PEO | Sassine Ghazi [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 8,810,795        
PEO | Sassine Ghazi [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (23,655,246)        
PEO | Sassine Ghazi [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
PEO | Sassine Ghazi [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,831,397)        
PEO | Sassine Ghazi [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (4,152,935)        
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (6,743,540)        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,408,279        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (7,519,039)        
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,632,780)        
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 0        
v3.25.4
Award Timing Disclosure
 12 Months Ended
Oct. 31, 2025
Award Timing Disclosures [Line Items]  
Award Timing MNPI Disclosure
Synopsys maintains equity grant timing guidelines for specifying the timing of equity grants, including option grants, made by the Compensation Committee and the Chief Executive Officer, who has been delegated the authority to make grants to employees who are not members of Synopsys’ Corporate Staff and Section 16 officers.
Annual grants of equity awards to members of Synopsys’ Corporate Staff and Section 16 officers, and direct reports of the CEO with a designation at or above Vice President (or equivalent level), are approved by the Compensation Committee at a pre-scheduled meeting in the first quarter of the fiscal year, and the effective grant date of such awards will be the meeting date unless the meeting date falls within a closed trading window, in which case the Compensation Committee will approve an effective grant date outside of the closed trading window. The effective grant date of new-hire, promotional or special recognition equity grants for such persons will be the approval date unless the approval date falls within a closed trading window, in which case the Compensation Committee will approve an effective grant date outside of the closed trading window.
With respect to equity awards granted to employees, other than members of Corporate Staff, Section 16 officers and direct reports of the CEO with a designation below Vice President (or equivalent level) made by the Chief Executive Officer pursuant to his delegation by the Compensation Committee, the grant effective date will be outside of Synopsys’ closed windows.
During fiscal 2025, no named executive officer received a grant of stock options during the period beginning four business days before, and ending one business day after, the filing of a periodic report on Form 10-Q or Form 10-K, or the filing or furnishing of a current report on Form 8-K that discloses material nonpublic information.
Award Timing Method
Annual grants of equity awards to members of Synopsys’ Corporate Staff and Section 16 officers, and direct reports of the CEO with a designation at or above Vice President (or equivalent level), are approved by the Compensation Committee at a pre-scheduled meeting in the first quarter of the fiscal year, and the effective grant date of such awards will be the meeting date unless the meeting date falls within a closed trading window, in which case the Compensation Committee will approve an effective grant date outside of the closed trading window. The effective grant date of new-hire, promotional or special recognition equity grants for such persons will be the approval date unless the approval date falls within a closed trading window, in which case the Compensation Committee will approve an effective grant date outside of the closed trading window.
With respect to equity awards granted to employees, other than members of Corporate Staff, Section 16 officers and direct reports of the CEO with a designation below Vice President (or equivalent level) made by the Chief Executive Officer pursuant to his delegation by the Compensation Committee, the grant effective date will be outside of Synopsys’ closed windows.
Award Timing Predetermined true
Award Timing MNPI Considered true
Award Timing, How MNPI Considered
Synopsys maintains equity grant timing guidelines for specifying the timing of equity grants, including option grants, made by the Compensation Committee and the Chief Executive Officer, who has been delegated the authority to make grants to employees who are not members of Synopsys’ Corporate Staff and Section 16 officers.
Annual grants of equity awards to members of Synopsys’ Corporate Staff and Section 16 officers, and direct reports of the CEO with a designation at or above Vice President (or equivalent level), are approved by the Compensation Committee at a pre-scheduled meeting in the first quarter of the fiscal year, and the effective grant date of such awards will be the meeting date unless the meeting date falls within a closed trading window, in which case the Compensation Committee will approve an effective grant date outside of the closed trading window. The effective grant date of new-hire, promotional or special recognition equity grants for such persons will be the approval date unless the approval date falls within a closed trading window, in which case the Compensation Committee will approve an effective grant date outside of the closed trading window.
With respect to equity awards granted to employees, other than members of Corporate Staff, Section 16 officers and direct reports of the CEO with a designation below Vice President (or equivalent level) made by the Chief Executive Officer pursuant to his delegation by the Compensation Committee, the grant effective date will be outside of Synopsys’ closed windows.
MNPI Disclosure Timed for Compensation Value false
v3.25.4
Insider Trading Policies and Procedures
 12 Months Ended
Oct. 31, 2025
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true